Advancing science and implementing novel, cutting edge Technologies

StemBANCC aims to provide well characterised patient derived induced pluripotent stem cell lines and associated biomaterials in an accessible and sustainable bio-bank. StemBANCC also aims to demonstrate proof of concept for the utility of induced pluripotent stem cells in drug discovery for hard-to-treat disorders.

StemBANCC has assembled a strong multidisciplinary team of top researchers from pharmaceutical companies, research institutions and small and medium enterprises to exploit the rich expertise across sectors and enhance knowledge transfer between academia and industry. The expertise of the team encompasses the range of skills required to deliver a top-notch research program and advance stem cell research for patient benefit. Drawn from different EU member states, cultures and backgrounds all of the members work together towards a common goal.

 

The Coordinator and Managing entity of StemBANCC are Martin Graf from F. Hoffmann–La Roche Ltd and Dr Zameel Cader from the University of Oxford.

 

  institut national de la santé et de la recherche médicale université de technologie de compiègne university of cambridge islensk erfdagreining ehf university of edinburgh janssen pharmaceutica nv Orion Corporation Linkopings Universitet Region Hovedstaden Glostrup Hospital Novo Nordisk A/S University of Newcastle upon Tyne University of Luebeck University of Oxford Charité Universitaetsmedizin Berlin Hannover Medical School (MHH) Medical Research Council Boehringer Ingelheim International GmbH AbbVie Deutschland GmbH & Co. KG Eli Lilly Merck KGaA King’s College London University College London Natural and Medical Sciences Institute at the University Tuebingen University of Birmingham Pfizer Limited Helmholtz Zentrum Meunchen concentris research management gmbh Université de Genève The Hebrew University of Jerusalem Tel Aviv University F. Hoffmann-La Roche Ltd Université de Lausanne Univercell-Biosolutions Innsbruck Medical University (IMU) Sanofi-Aventis Recherch & Development Image Map
Partners
Town
Country
Basel
Switzerland
Oxford
United Kingdom
Fürstenfeldbruck
Germany
London
United Kingdom
London
United Kingdom
Toulouse
France
Edinburgh
United Kingdom
Birmingham
United Kingdom
Neuherberg
Germany
Luebeck
Germany
Newcastle upon Tyne
United Kingdom
Lausanne
Switzerland
Geneva
Switzerland
Cambridge
United Kingdom
Tel Aviv
Israel
Linkoping
Sweden
Wiesbaden - Delkenheim
Germany
Beerse
Belgium
Basingstoke
United Kingdom
Darmstadt
Germany
Bagsvaerd
Denmark
Espoo
Finnland
Kent
United Kingdom
Swindon
United Kingdom
Södertälje
Sweden
Newcastle upon Tyne
United Kingdom

The Scientific and Ethical Advisory Board (SAB) consists of five international leading experts in the field. The Board is a consultative body to ensure and improve the scientific performance and the quality of results.  It will also monitor and consult the consortium on any ethical issues.

  • Prof. Beatriz SILVA LIMA
    Lisbon University, Faculty of Pharmacy, Portugal
  • Prof. Kevin EGGAN
    Harvard University, Department of Stem Cell and Regenerative Biology, United States
  • Prof. Leif GROOP
    Lund University, Diabetes Centre, Sweden
  • Dr. Glyn STACEY
    National Institute for Biological Standards and Control, Division of Cell Biology, United Kingdom
  • Prof. Nils HOPPE
    Leibniz University Hannover, Centre for Ethics and Law in the Life Sciences, Germany

Coordinator of StemBANCC

Martin Graf (F. Hoffmann–La Roche Ltd) is the Coordinator of StemBANCC. The Coordinator is responsible for the overall scientific progress of the project and the quality of the results. In his role as coordinator Martin Graf is the chair of the Steering Committee and the General Assembly.

 

Martin Graf
Head of Stem Cell Platform
F. Hoffmann-La Roche Ltd
Discovery Technologies, PROBSH
Building 70/9
Ch-4070 Basel
E-Mail  

 


Managing entity of StemBANCC

Dr Zameel Cader (University of Oxford) is the StemBANCC Managing entity of the IMI JU funding. As the leader of the academic and SME participants in the consortium, he is responsible for the scientific management and the supervision of the overall progress in collaboration with the coordinator.

 

Dr. Zameel Cader

Nuffield Department of Clinical Neurosciences

Level 6 West Wing, John Radcliffe Hospital
Headley Way
Oxford OX3 9DU
United Kingdom

E-Mail  

 


Project management office

The StemBANCC Project management office consists of Martin Graf at F. Hoffmann-La Roche Ltd in Basel, Zameel Cader at the University of Oxford and Barbara Heißerer at concentris in Fürstenfeldbruck. The Project office is responsible for the scientific management of the project and the day-to-day coordination of all StemBANCC activities. Barbara Heißerer as project manager at concentris takes care of the financial and overall project management.

 

Dr. Barbara Heißerer
concentris research management gmbH
Ludwigstr. 4
D-82256 Fürstenfeldbruck
Germany
E-Mail  

 

Left to right: Zameel Cader, Barbara Heißerer, Martin Graf

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Until you give your consent, only those cookies necessary to maintain the website's functionality are active. When you choose "OK", so called third-party non-functional cookies (e.g. GDPR-conform Google Analytics) may also become active. Please be aware that the website's functionality may be restricted if you choose "DECLINE". You can revoke your choice at any time by clearing your browser cache/history and updating your selection. Please also view our privacy policy.
Ok Decline